People · Operator
Named in public records as an officer, director or promoter · active 2010–2026 · Biotech / Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fairfield Bio, Inc. | — | Biotech / Pharma | Pre-Seed | $450K | $797K | 2026 |
| Starling, Inc. | — | Other Technology | Pre-Seed | $200K | $8.5M | 2010 |
Kevin Slavin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Slavin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth Miller | 1 | 8 |
| Mitchell Wolfe | 1 | 1 |
| Arnaud Loiseau | 1 | 1 |
| Peter Hirshberg | 1 | 1 |
| Declan Caulfield | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.